Senator Investment Group LP Acquires New Shares in Danaher Corporation $DHR

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Senator Investment Group LP bought a new position in Danaher Corporation (NYSE:DHR - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 200,000 shares of the conglomerate's stock, valued at approximately $41,000,000. Danaher comprises about 2.2% of Senator Investment Group LP's investment portfolio, making the stock its 20th biggest position.

Several other large investors also recently modified their holdings of DHR. Nuveen LLC bought a new stake in shares of Danaher in the first quarter worth about $833,941,000. GAMMA Investing LLC grew its stake in shares of Danaher by 24,958.2% in the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after purchasing an additional 1,863,381 shares during the last quarter. Two Sigma Advisers LP grew its stake in shares of Danaher by 4,248.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after purchasing an additional 1,601,800 shares during the last quarter. Invesco Ltd. grew its stake in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Danaher by 460.6% during the 4th quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock valued at $309,558,000 after acquiring an additional 1,107,998 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on DHR shares. HSBC cut their price objective on Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. Barclays reaffirmed an "overweight" rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. The Goldman Sachs Group cut their price objective on Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Deutsche Bank Aktiengesellschaft cut their price objective on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Finally, Wells Fargo & Company cut their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $247.61.

Danaher Stock Down 3.4%

Shares of DHR stock traded down $7.2480 during trading hours on Thursday, hitting $204.1520. 3,172,582 shares of the company's stock traded hands, compared to its average volume of 4,191,163. The stock's fifty day simple moving average is $200.45 and its two-hundred day simple moving average is $199.55. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The stock has a market cap of $146.18 billion, a price-to-earnings ratio of 43.44, a PEG ratio of 2.95 and a beta of 0.73. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period last year, the business earned $1.72 earnings per share. The business's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.